Correspondence to:

Idiopathic pulmonary fibrosis (IPF) is a chronic irreversibly progressive fibrosing lung disease of unknown etiology leading to death all patients affected with a reported median survival of 3 years post diagnosis1,2. Five year survival of IPF patients is estimated at 30%, much worse than that of many common neoplasms such as breast and prostate cancer and similar to that of lung cancer3. The need for appropriate management and treatment of IPF patients appears imperative and urgent due to the high mortality rate of the disease. Up to now the only therapeutic approach proved to increase survival was lung transplantation1,2. The therapeutic strategy with triple combination with steroids, azathio-prine and n-acetyl cysteine proved harmful for the treatment of IPF patients as shown by the interim analysis of the PANTHER trial that demonstrated significant increase of the risk of death, hospitalizations, exacerbations and other major complications at the treated group compared to the placebo arm of the study4. Based on the above mentioned data, triple therapy is not recommended anymore in many European countries, such as France